Intuitive Surgical, Inc. (ISRG) has been a focal point in the market following its strong recent performance, with a surge in stock value by 40%. The improvement is driven by Surging da Vinci Utilization and new FDA wins, cementing its reputation as a viable 'Buy and Hold' for long-term outperformance. Renowned institutions like Bernstein, RBC Capital, BTIG and Baird have reiterated their bullish stance on ISRG by raising their price targets. Most notably, Bernstein raised its projection to $740. Investors have consistently shown their faith in the company's growth, especially due to the latest FDA clearance expanding da Vinci SP into general surgery. However, there is cautious commentary due to its high premium P/E ratio and consistent surge in share prices. The company's stock fell marginally due to concerns, but quickly rebounded, signaling that it's still undervalued. Recent FDA greenlight for the medical robotics pioneer further enhances the positive sentiments. Despite certain adversities, firm fundamentals and high margins make ISRG a popular choice, with the company rating as an 'Outperform' by Bernstein SocGen Group.
Intuitive Surgical ISRG News Analytics from Wed, 10 Sep 2025 07:00:00 GMT to Sat, 10 Jan 2026 21:37:00 GMT -
Rating 8
- Innovation 7
- Information 9
- Rumor -7
